The interaction between the (epi)genetic makeup of an individual and his/her environmental exposure record (exposome) is accepted as a determinant factor for a significant proportion of human malignancies. Recent evidence has highlighted the key role of epigenetic mechanisms in mediating gene-environment interactions and translating exposures into tumorigenesis. There is also growing evidence that epigenetic changes may be risk factor-specific ("fingerprints") that should prove instrumental in the discovery of new biomarkers in cancer. Here, we review the state of the science of epigenetics associated with environmental stimuli and cancer risk, highlighting key developments in the field. Critical knowledge gaps and research needs are discussed and advances in epigenomics that may help in understanding the functional relevance of epigenetic alterations. Key elements required for causality inferences linking epigenetic changes to exposure and cancer are discussed and how these alterations can be incorporated in carcinogen evaluation and in understanding mechanisms underlying epigenome deregulation by the environment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027626PMC
http://dx.doi.org/10.1002/ijc.31014DOI Listing

Publication Analysis

Top Keywords

epigenome deregulation
8
epigenetic changes
8
epigenetic
5
roadmap investigating
4
investigating epigenome
4
deregulation environmental
4
environmental origins
4
cancer
4
origins cancer
4
cancer interaction
4

Similar Publications

Targeting Epigenetic Dysregulations in Head and Neck Squamous Cell Carcinoma.

J Dent Res

December 2024

Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY, USA.

Head and neck squamous cell carcinoma (HNSCC) is one of the deadliest human cancers, with the overall 5-year survival rate stagnating in recent decades due to the lack of innovative treatment approaches. Apart from the recently Food and Drug Administration-approved epidermal growth factor receptor inhibitor and immune checkpoint inhibitor, alternative therapeutic strategies that target epigenetic abnormalities, an emerging cancer hallmark, remain to be fully explored. A pathological epigenetic landscape, characterized by widespread reprogramming of chromatin modifications such as DNA methylation and histone modifications, which drives transcription deregulation and genome reorganization, has been extensively documented in numerous cancers, including HNSCC.

View Article and Find Full Text PDF

DNMT3A and TET2 are epigenetic regulator genes commonly mutated in age-related clonal hematopoiesis (CH). Despite having opposed epigenetic functions, these mutations are associated with increased all-cause mortality and a low risk for progression to hematological neoplasms. While individual impacts on the epigenome have been described using different model systems, the phenotypic complexity in humans remains to be elucidated.

View Article and Find Full Text PDF
Article Synopsis
  • Two mouse models, one with translated (HD/100Q) and one with nontranslated (HD/100CAG) human mutant HTT, were created to study their effects on behavior and molecular changes over 21 months.
  • Results showed both models displayed behavioral alterations and gene deregulations, with the nontranslated model exhibiting less severe impairments but notable anxiety increases due to mutant HTT RNA, suggesting its minor role in HD pathogenesis.
View Article and Find Full Text PDF

Aging presents a significant challenge to health and social care systems due to the increasing proportion of the elderly population. The identification of reliable biomarkers to assess the progression of aging remains an unresolved question. Circular RNAs (circRNAs) are single-stranded covalently closed RNAs.

View Article and Find Full Text PDF

Advances in Epigenetic Therapeutics for Breast Cancer.

Adv Exp Med Biol

November 2024

Department of Medical Microbiology and Immunology, University of California Davis School of Medicine, Davis, CA, USA.

Article Synopsis
  • Epigenetic changes play a significant role in breast cancer by contributing to tumor growth, resistance to treatments, and spreading of cancer cells.
  • There is an increasing focus on developing therapies that target these epigenetic mechanisms as a new approach to combat breast cancer.
  • This chapter discusses various strategies, including the use of selective inhibitors and combining epigenetic therapies with traditional treatments, as well as recent research advancements in this area.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!